glp-1 adherence abandonment rates remain high despite booming demand GLP-1 Adherence: How Providers Manage
Description
Anti-interleukin-21 antibody and liraglutide for the preservation of -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
Governments looking to reduce the costs of healthcare and boost economic productivity also need to tread carefully when encouraging the use of GLP-1 drugs in people with obesity without addressing the wider socio-economic challenges patients face as well as the problems posed by the rise in ultra-processed food and poor provision of physical exercise facilities
Diabetes Obes Metab 25(1):5667 Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
It plays an important role in weight management and related health conditions
PSM with age, sex, race, and disease comorbidities was then conducted, yielding 162,253 matched patients for analysis
